ReviewChembiochem : a European journal of chemical biology2020
Rhenium-Based Complexes and in Vivo Testing: A Brief History.
Review in Chembiochem : a European journal of chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Rhenium in Wild Mushrooms: Environmental Occurrence and Censoring-Aware Quantification.International journal of molecular sciences · 2026Article
- Metal-based triazoles as a medical marvel of the modern era: a comprehensive review.RSC advances · 2026Review
- An Investigation to Identify the Anti-Cancer Properties of Novel Rhenium Compounds in Prostate and Lung Cancer Cell Lines.Journal of biotechnology and biomedicine · 2026Article
- Rhenium(I) Complexes with 2-(1,2,4-Triazol-5-yl)-International journal of molecular sciences · 2025Article
- Ru(II) Complexes with 3,4-Dimethylphenylhydrazine: Exploring In Vitro Anticancer Activity and Protein Affinities.Biomolecules · 2025Article
- Novel Re(I) Complexes as Potential Selective Theranostic Agents in Cancer Cells andJournal of medicinal chemistry · 2024Article
- Structural Effect of Rhenium- and Iridium-Complex Liposome Composition on Their Selectivity for Antimicrobial Photodynamic Therapy.Small science · 2024Article
- Rhenium(I) Tricarbonyl Complexes of 1,10-Phenanthroline Derivatives with Unexpectedly High Cytotoxicity.Inorganic chemistry · 2023Article
- Metal-Based Complexes in Cancer.International journal of molecular sciences · 2023Article
- Target-specific mononuclear and binuclear rhenium(i) tricarbonyl complexes as upcoming anticancer drugs.RSC advances · 2022Review
- Challenges and opportunities in the development of metal-based anticancer theranostic agents.Bioscience reports · 2022Review
- Synthesis, Characterization and Antitumor Mechanism Investigation of Heterometallic Ru(Ⅱ)-Re(Ⅰ) Complexes.Frontiers in chemistry · 2022Article
- Origin of Increased Reactivity in Rhenium-Mediated Cycloadditions of Tetrazines.The Journal of organic chemistry · 2021Article
- ReAngewandte Chemie (International ed. in English) · 2021Article
- Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling.Journal of experimental & clinical cancer research : CR · 2020Article
- Mitochondria-targeted Re(I) complexes bearing guanidinium as ligands and their anticancer activity.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2020Article
- Recent Emergence of Rhenium(I) Tricarbonyl Complexes as Photosensitisers for Cancer Therapy.Molecules (Basel, Switzerland) · 2020Review
- Influence of the Nucleophilic Ligand on the Reactivity of Carbonyl Rhenium(I) Complexes towards Methyl Propiolate: A Computational Chemistry Perspective.Molecules (Basel, Switzerland) · 2020Article
- Rhenium-Based Complexes and in Vivo Testing: A Brief History.Chembiochem : a European journal of chemical biology · 2020Review
- Exploring the In Vivo and In Vitro Anticancer Activity of Rhenium Isonitrile Complexes.Inorganic chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of metal-based anticancer therapeutics in the treatment of cancer is best exemplified by cisplatin. Currently used in 32/78 cancer regimens, metal-based drugs have a clear role in cancer therapy. Despite this, metal-based anticancer therapeutics are not without drawbacks, with issues such as toxic side effects and the development of resistance mechanisms. This has led to investigations of other metal-based drug candidates such as auranofin, a gold-based drug candidate as well as ruthenium-based candidates, NAMI-A, NKP-1339 and TLD-1433. All are currently undergoing clinical trials. Another class of complexes under study are rhenium-based; such complexes have undergone extensive in vitro testing but only nine have been reported to display antitumour in vivo activity, which is a necessary step before entering clinical trials. This review will document, chronologically, the rhenium-based drug candidates that have undergone in vivo testing and the outlook for such complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.